1. Introduction {#s0005}
===============

Although psychotic disorders are highly heritable ([@bb0060; @bb0225; @bb0275; @bb0100]) understanding their specific genetic causes has proven harder than anticipated ([@bb0145]). It is only recently that the first genetic risk factors have been identified through large international collaborative efforts; however, little is known about the role of the associated loci ([@bb0280; @bb0330; @bb0265; @bb0355; @bb0335]). The use of endophenotypes, which are heritable biological markers characterising the disease ([@bb0120]), could lead to a better understanding of the mechanisms through which variation in these genes leads to the disease ([@bb0045; @bb0135; @bb0115]).

Electroencephalography (EEG) measures ongoing electrical brain activity, and provides a possible basis for endophenotypes of brain function associated with psychosis ([@bb0030; @bb0360; @bb0140]). Several such measures are highly heritable ([@bb0365; @bb0395; @bb0040]) and some event-related potentials have been shown to be promising endophenotypes for psychotic disorders ([@bb0050; @bb0290; @bb0370; @bb0075; @bb0300]). This study focused on quantitative EEG (QEEG) at rest, where psychiatric patients have shown abnormal patterns of activity compared to healthy controls ([@bb0170; @bb0070; @bb0040]).

Relatively little research has been conducted on resting QEEG activity in patients with psychosis, especially in populations at-risk for the illness, and results have been inconsistent and sometimes even contradictory ([@bb0125; @bb0040]). Nonetheless, psychotic patients generally exhibit increased slow wave QEEG activity in the delta (1--4 Hz) and theta (4--8 Hz) bands ([@bb0340; @bb0345; @bb0380; @bb0210; @bb0150; @bb0025; @bb0160]), and decreased alpha (8--13 Hz) activity ([@bb0350; @bb0150; @bb0025]). In terms of resting beta (13--21 Hz) activity, results are inconsistent, with studies reporting both decreased ([@bb0190]) and increased ([@bb0385; @bb0025]) activity, as well as no abnormalities in patients with psychosis ([@bb0340; @bb0380; @bb0240; @bb0160]). It is therefore unclear whether resting QEEG represents a useful endophenotype for psychosis, which speaks to the need for further research in this area.

The aim of this study was to investigate the role resting QEEG abnormalities play in the aetiology of psychosis, and whether it can provide an endophenotype for the illness. Quantitative EEG amplitudes at rest were compared across four frequency bands, between five groups; chronic psychotic patients, first episode patients, individuals at-risk of developing psychosis, unaffected relatives of patients, and healthy controls. Psychosis was broadly defined, including patients with schizophrenia, bipolar disorder (with a history of psychotic symptoms), schizoaffective disorder, as well as other psychotic illnesses. Based on past findings, it was hypothesised that amplitudes in delta and theta frequency bands would be increased, and amplitude in the alpha band would be reduced, in patients with psychosis as well as in populations at risk, compared to healthy controls. In the beta frequency band, no direction of abnormalities was predicted. Impairments were predicted to be most severe in the patients.

2. Method and materials {#s0040}
=======================

2.1. Sample and clinical assessments {#s0010}
------------------------------------

The total sample of 279 participants was recruited from the South London and Maudsley NHS Foundation Trust (including "Outreach and Support in South London" and the Lambeth Early Psychosis Intervention service), as well as through collaboration with the charity Re-Think ([www.rethink.org](http://www.rethink.org){#ir0030}), and advertisements in the local and national media.

All participants were clinically interviewed to confirm or exclude a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) ([@bb0015]) diagnosis. The interview instruments used were the Structured Clinical Interview for DSM Disorders (SCID) ([@bb0090]) or the Schedule of Affective Disorders and Schizophrenia Lifetime Version (SADS-L) ([@bb0085]), and the Positive and Negative Syndrome Scale (PANSS) ([@bb0200]). Information regarding psychiatric diagnoses of family members not directly assessed was collected from the most reliable informant(s) with the Family Interview for Genetic Studies ([@bb0230]). Additional information was collected from medical notes where available. Participants were excluded if they had a diagnosis of alcohol or substance dependence in the 12 months preceding study entry, any neurological disorders, or head injury with loss of consciousness for more than a few minutes.

The total sample included five groups. At the time of testing, chronic patients (N = 48) had been ill for more than three years, and first episode patients (N = 46) less than three years. The cut-off of 3 years reflects the maximum amount of time our local Early Intervention Service -- where the first episode patients were recruited from -- followed up their patients. This is comparable to other early psychosis research ([@bb0325; @bb0285]). A full breakdown of the diagnoses in these two patient groups can be found in [Table 1](#t0005){ref-type="table"}. Individuals with an "at risk mental state" (ARMS, N = 33) were assessed using criteria in the Comprehensive Assessment for At Risk Mental State (CAARMS) ([@bb0390; @bb0245]).

Healthy first-degree relatives of chronic patients (N = 45) had no personal history of any psychosis spectrum illness. Healthy controls (N = 107) had no personal or family history of any psychotic disorders. Having a personal history of other non-psychotic psychiatric illnesses did not constitute an exclusion criteria for relatives or controls, provided they were well and not taking any psychotropic medication at the time of testing and for the preceding 12 months. This was to avoid recruiting biased control groups, unrepresentative of the local population.

After a complete description of the study, all participants gave their written informed consent. The study was approved by the Research Ethics Committee at the Institute of Psychiatry, King\'s College London.

2.2. EEG data acquisition {#s0015}
-------------------------

Resting EEG data was collected using either a 64-channel Synamps or a 40-channel Nuamps amplifier and respectively 64 or 40 channel quick caps with sintered silver/silver-chloride electrodes, placed according to the International 10/20 system ([@bb0185]). All data was continuously digitised at 1000 Hz, with a 0--200 Hz band-pass filter. Electrode impedances were kept below 5 kΩ ([@bb0055; @bb0300]).

For EEG data collected from 40 channels, unipolar electrodes placed on the outer canthi of both eyes, and above and below the left eye monitored eye movements. Linked ear lobes served as reference, and FPZ was the ground ([@bb0105]). For EEG data collected using 64 channels, bipolar vertical and horizontal electro-oculographs monitored eye movements. Bilateral mastoids served as reference, and AFZ was the ground ([@bb0055; @bb0310]).

EEG recordings were collected in a quiet room with participants sitting down comfortably. They were asked to keep their eyes closed for 20 s and then open for 20 s, during a total of 5 min. Resting EEG data collection was followed by other EEG procedures reported elsewhere (e.g. [@bb0290; @bb0305; @bb0080]).

2.3. Data processing {#s0020}
--------------------

Signal processing was conducted using Neuroscan 4.3 software ([www.neuroscan.com](http://www.neuroscan.com){#ir0035}) and MATLAB ([www.mathworks.co.uk](http://www.mathworks.co.uk){#ir0040}). Sequential epochs of 2048 ms were created from the continuous EEG files, separately for eyes-open and eyes-closed conditions. Automatic artefact detection rejected sweeps with activity exceeding ± 100 μV ([@bb0270]). EEG amplitude (μV) was calculated using the Fast Fourier Transformation using a Hanning window with 10% taper length. Only the EEG segments required under eyes-closed conditions were included in further statistical analyses --- to suppress the effect of ocular artefacts ([@bb0400; @bb0220]). After artefact rejection and exclusion of eyes open data, on average 101 s remained per subject for analysis (mean = 101.20, SD = 29.33). This did not differ between groups.

Amplitude was analysed for four individual segments of the EEG spectrum; delta (1.95--3.90 Hz), theta (4.39--7.32 Hz), alpha (8.30--12.70 Hz), and beta (13.20--21.00 Hz). These frequency bands are typical of similar research ([@bb0040]), except that we chose not to analyse frequencies above 21 Hz. This was due to accumulating evidence that frequencies above 21 Hz can still be substantially contaminated by scalp electromyogram activity (EMG), even after rejection of large EMG bursts ([@bb0375; @bb0295; @bb0255]).

For data-reduction purposes (to minimize type I error), only the three midline EEG channels, frontal (FZ), central (CZ), and parietal (PZ), were chosen for statistical analysis ([@bb0150]).

2.4. Statistical analysis {#s0025}
-------------------------

Mixed effects linear regression models were used to examine EEG amplitude, separately for each frequency band, with fixed effects of clinical group and scalp site, and random effects of family and subject. Hence, correlations between members of the same family were modelled, to maintain correct type-1 error rates. The dependent variable was EEG amplitude in μV at each of the four frequency bands (delta, theta, alpha, and beta). The independent variables were participant group --- a between-subjects variable with five levels (chronic patients, first episode patients, ARMS, relatives, and controls), and region --- a within-subjects variable with three levels (FZ, CZ, and PZ). Age and gender were controlled for (as nuisance regressors) in all analyses. Since EEG data were collected using two different laboratories, due to an upgrade of the EEG equipment, this was also controlled for; by including a binary regressor in the analysis. The control group and FZ were used as reference categories in all inferential tests.

A Bonferroni correction for four tests (delta, theta, alpha, and beta frequency bands) was applied, with the significance threshold thus set to p = 0.05/4 = 0.0125. Statistical analyses were performed using STATA version 11.2 ([www.stata.com](http://www.stata.com){#ir0045}) and SPSS version 17.1 ([www.spss.com](http://www.spss.com){#ir0050}).

3. [R]{.smallcaps}esults {#s0045}
========================

3.1. Sample characteristics {#s0030}
---------------------------

Demographic data for the entire sample is provided in [Table 1](#t0005){ref-type="table"}. T-tests showed that each group differed significantly from the control group in mean age, with the chronic patients and relatives being older (both groups p \< 0.001), and the first episodes and at-risk mental state (ARMS) individuals being younger (p \< 0.001) than controls. Chi square tests indicated that there were significantly more males in the first episode group in comparison to the control group (p = 0.05). No other group differed in gender distribution compared to controls. To control for any age or gender effects on the resting EEG, we included these effects as covariates in all analyses. As described in [Table 1](#t0005){ref-type="table"}, the majority of chronic and first episode patients were taking antipsychotics at the time of testing, whereas the relatives, ARMS and controls were free of any psychotropic medication at the time of testing.

The mean EEG amplitudes (μV) for each group, in the four frequency bands, are shown in [Table 2](#t0010){ref-type="table"}. All EEG outcome measures were log-transformed (log10 + 1) to ensure normality of random effects. Correlations between EEG amplitude in the four frequency bands and the three scalp sites were all significant, with correlation coefficients ranging between 0.21 and 0.99 (see Supplementary material). Nevertheless, we adjusted all our analyses for multiple testing (4 tests).

Most participants (first episodes, ARMS, and controls) were recruited individually, but the chronic patients and their relatives were recruited as part of a family study. Of the 279 participants, 174 (62.37%) were singletons, 72 (25.81%) were part of families with two members in the study, 21 (7.53%) were in three-person families, and 12 (4.30%) were part of families with four members participating.

3.2. Mixed effects linear regression {#s0035}
------------------------------------

Four mixed effects linear regression models were analysed. In the delta band, chronic patients had on average 0.208 μV greater amplitude than controls, which was statistically significant (p \< 0.001; Est. diff: 0.082 log μV; 95% CI 0.046--0.118 log μV). No other group differed significantly from the control group in resting delta EEG amplitude.

In the theta frequency band chronic patients had significantly greater resting amplitude compared to controls (p \< 0.001; Est. diff: 0.136 log μV; 95% CI 0.083--0.190 log μV), with a 0.368 μV average increase in amplitude. No other group differed significantly from the controls in resting theta activity

In the alpha and beta frequency bands, the control group did not differ significantly from any other group in resting EEG amplitude.

[Fig. 1](#f0005){ref-type="fig"} shows EEG amplitudes (μV) across the five groups, for all four frequency bands. Full details of these results, including main effects of covariates, can be found in the Supplementary material. Importantly, the effect of the two different EEG laboratories used for data collection was not significant in any frequency band, justifying pooling the two datasets in one analysis.

Since a broad definition of psychosis was used in this study, the analyses were repeated using a narrow definition of schizophrenia and schizophreniform psychosis, to investigate whether this would affect the results. We excluded all patients with a diagnosis of schizoaffective disorder, brief psychotic disorder, bipolar I disorder, and psychotic disorder not otherwise specified (15 chronic and 8 first episode patients), as well as their relatives (14). These analyses led to results very similar to those using the full dataset, and have not been reported further.

To further investigate potential differences in resting EEG between the groups, we repeated the 4 regression models post-hoc, using the chronic patient group as the reference category. These results are presented in the Supplementary material for the interested reader.

4. Discussion {#s0050}
=============

The aim of the current study was to compare quantitative EEG (QEEG) activity at rest in four frequency bands, in patients with psychosis, two populations at-risk of the disease, and healthy controls, to investigate whether QEEG could be used as possible endophenotypes for the illness. The main significant findings are summarised in [Table 3](#t0015){ref-type="table"}.

Our a-priori hypotheses were partly supported; chronic patients showed significantly increased resting delta and theta activity compared to healthy controls. However, first episode patients, individuals with an at-risk mental state (ARMS), and relatives of chronic patients did not differ from controls in these frequencies. Furthermore, there were no significant group differences in resting alpha or beta QEEG activity.

Increased slow wave resting QEEG activity in delta and theta bands in chronic patients with psychosis appears to be fairly well replicated across studies ([@bb0340; @bb0260; @bb0345; @bb0380; @bb0210; @bb0150; @bb0025; @bb0160]), and supported by our current results. However, our study did not find any significant differences in delta or theta resting activity between the control group and first episode patients or at-risk populations (including both clinically at-risk and genetically predisposed groups). Previous studies on such groups are limited, with inconclusive findings. Abnormalities similar to chronic patients have been observed in first episode patients ([@bb0065; @bb0340]), ARMS ([@bb0130]) and healthy controls ([@bb0010]), but several studies have also failed to show abnormalities in these populations ([@bb0380; @bb0385; @bb0150]). [@bb0190] found, similarly to our results, that chronic but not first episode schizophrenic patients had increased delta and theta resting activity.

In comparison to the slower frequencies, less research has been conducted on resting alpha QEEG activity in psychosis. As in our study, [@bb0240] reported no evidence of alpha impairments in patients. However, several previous studies on resting alpha have found a decrease in activity in psychotic patients compared to healthy controls ([@bb0260; @bb0350; @bb0150; @bb0025]).

In the beta frequency band, we did not find any significant group differences in resting QEEG activity. However, a slight increase of activity was observed in chronic patients compared to controls (not reaching significance after correction for multiple testing), and post-hoc comparison between chronic and first episode patients revealed an increase of beta activity in the former group at a trend level (see Supplementary material). Together this might indicate an abnormality in chronic psychotic patients, although more research is needed to confirm if this is the case. The literature on resting beta activity in psychosis is inconsistent, with several studies reporting no resting beta abnormalities in psychotic patients ([@bb0340; @bb0380; @bb0240; @bb0160]), although both decreased ([@bb0190]) and increased ([@bb0385; @bb0025]) activity has also been observed. Finally, our study did not find any differences in beta amplitude between controls and first episode patients or at-risk populations. Past research on such populations has also largely failed to find significant impairments in these groups ([@bb0340; @bb0380; @bb0150; @bb0160]).

Taken together, the current results did not show any statistically significant differences in resting QEEG activity of any frequency band between controls and first episode patients or at-risk populations, including ARMS and unaffected relatives of psychotic patients. This indicates, as also argued by [@bb0380], that low frequency QEEG abnormalities seen in chronic psychotic patients are likely related to the illness process, or to long-term effects of treatments, rather than to genetic risk for the disorder. Hence, resting QEEG activity (of the four frequency bands examined) does not appear to be promising candidate endophenotypes for genetic research in psychosis.

Nevertheless, low frequency resting QEEG abnormalities, in the delta and theta bands, were observed in chronic psychotic patients compared to healthy controls. This could be a useful biomarker in non-genetic research, perhaps investigating chronicity of the illness or cognitive deficits characterising psychosis, which are often associated with an enduring illness ([@bb0175; @bb0180]), or research into prediction of medication-responses. More research is needed to investigate this.

From an aetiological perspective, our findings of increased low-frequency activity (and previous reports of similar abnormalities) are consistent with recent theoretical treatments of psychosis as false perceptual inference ([@bb0095; @bb0005]). In this formulation, acute psychotic symptoms are regarded as a compensation for a failure of sensory attenuation. In other words, psychotic symptoms arise due to assigning too much salience or precision to high level representations to compensate for precise sensory (low level) inputs (c.f., aberrant salience; [@bb0165]). In this setting, negative symptoms or chronic states are seen as a decompensation, with a relative loss of precision at higher levels of the neuronal hierarchy. In this context, precision corresponds to the post-synaptic gain of pyramidal cells reporting prediction errors in hierarchical predictive coding ([@bb0020; @bb0005]). This is important because a decrease in postsynaptic gain or efficacy leads to a preponderance of lower frequencies relative to higher frequencies in endogenous or resting state activity ([@bb0205]). In short, our chronic group may be evidencing reduced synaptic gain at higher hierarchical levels and a shift in the characteristic frequencies of neuronal fluctuations to lower frequencies. Whether this is a primary aetiological factor, a characteristic part of the disease process, or a response to medication remains an open question.

Importantly, since antipsychotic drugs cross the blood--brain barrier and influence many parameters of brain function (e.g. [@bb0195; @bb0215]), it is possible that these medications contribute or lead to resting QEEG abnormalities observed in psychotic patients. This could be an important confounder in our current findings, suggesting that true illness-related effects on resting EEG are nuanced by medication. However, it has also been argued that antipsychotics are unlikely to account for QEEG abnormalities seen in chronic patients, since such alterations have also been found in unmedicated patients ([@bb0260; @bb0235; @bb0385; @bb0040]). Since both the chronic and the first episode patient groups were medicated in the current sample, medication effects alone do not appear to fully explain why no abnormalities were observed in the latter group. Nevertheless, the effects of antipsychotic drugs on resting QEEG activity needs further investigation in longitudinal studies, and it is possible that long-term effects of treatment is a confounding factor when interpreting our current results.

Important considerations of statistical power need to be acknowledged. Calculations of effect sizes are hampered by the few studies available looking at populations at-risk of developing psychosis. Deficits in such populations are likely to be subtler than those in chronic patients. This has been shown to be true for, for example, the P300 event related potential (ERP) peak amplitude ([@bb0050]) and the error-related negativity ERP ([@bb0315]), and electrophysiological measures of cortical inhibition ([@bb0155]). Furthermore, only a minority of individuals with an at-risk mental state will go on to develop psychosis ([@bb0320; @bb0110; @bb0250]), making abnormalities in this population difficult to detect. This was clearly observed in a study by [@bb0035] where only at-risk individuals who later converted to psychosis showed EEG abnormalities compared to healthy controls, whereas, similarly to our findings, the overall at-risk group did not differ from controls. Hence, it may be assumed that effect sizes for possible resting EEG abnormalities in at-risk populations are smaller than those in patients. This, in turn, suggests that the current study might have been underpowered to detect true yet subtle differences between healthy controls and at-risk groups.

In conclusion, we set out to characterise resting EEG oscillations (QEEG) in psychosis and populations at risk for this disease and particularly, whether such measures could act as candidate endophenotypes for the illness. Our results provide evidence that chronic psychotic patients exhibit resting QEEG abnormalities in low frequencies. However, no abnormalities were observed in first episode patients or at-risk populations, suggesting that resting QEEG activity is not likely related to genetic risk for the illness. Instead, abnormalities observed in chronic patients may be related to the illness process, or to long-term effects of treatment. Hence, results from this study indicate that resting QEEG activity is not an appropriate candidate endophenotype for genetic research in psychosis, although low frequency activity could be a potential biomarker for non-genetic research, for example as prognostic or medication-response predictors.
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![Resting EEG amplitude (μV) in the four frequency bands and the five participant groups, uncorrected for covariates.](gr1){#f0005}

###### 

Sample demographics (N = 279).

                                                                   Chronic patients       First episode patients   ARMS                                         Relatives              Controls
  ---------------------------------------------------------------- ---------------------- ------------------------ -------------------------------------------- ---------------------- ---------------
  *N* (% of total sample)                                          48 (17.2%)             46 (16.5%)               33 (11.8%)                                   45 (16.1%)             107 (38.4%)
  *Age* (mean years ± SD)                                          41.8 ± 11.3            25.0 ± 3.9               23.8 ± 4.0                                   48.8 ± 16.1            31.6 ± 13.3
  Statistics (p value)[a](#tf0005){ref-type="table-fn"}            t = − 4.6 (\< 0.001)   t = 4.7 (\< 0.001)       t = 5.4 (\< 0.001)                           t = − 6.3 (\< 0.001)   
  *Gender* (% male, male/female)                                   64.6% (31/17)          69.6% (32/14)            60.6% (20/13)                                44.4% (20/25)          51.4% (55/52)
  Statistics (p value)[a](#tf0005){ref-type="table-fn"}            χ^2^ = 2.3 (0.16)      χ^2^ = 4.3 (0.05)        χ^2^ = 0.9 (0.43)                            χ^2^ = 0.6 (0.48)      
                                                                                                                                                                                       
  *Diagnoses* (N, % of group)                                                                                                                                                          
  Schizophrenia                                                    33 (68.8%)             12 (26.1%)               --                                           --                     --
  Schizoaffective disorder                                         8 (16.7%)              1 (2.2%)                 --                                           --                     --
  Brief psychotic disorder                                         1 (2.1%)               --                       --                                           --                     --
  Schizophreniform psychosis                                       --                     26 (56.5%)               --                                           --                     --
  Bipolar I Disorder                                               5 (10.4%)              4 (8.7%)                 --                                           --                     --
  Psychotic disorder NOS                                           1 (2.1%)               3 (6.5%)                 --                                           --                     --
  "At risk mental state"[b](#tf0010){ref-type="table-fn"}          --                     --                       33 (100.0%)                                  --                     --
  Non-psychotic depressive illness (incl. MDD)                     --                     --                       9 (27.3%)[c](#tf0015){ref-type="table-fn"}   17 (37.8%)             7 (6.5%)
  Anxiety disorder (incl. GAD)                                     --                     --                       3 (9.1%)[c](#tf0015){ref-type="table-fn"}    5 (11.1%)              --
  Substance Abuse                                                  --                     --                       4 (12.1%)[c](#tf0015){ref-type="table-fn"}   --                     1 (0.1%)
  Personality Disorder                                             --                     --                       2 (6.1%)[c](#tf0015){ref-type="table-fn"}    --                     --
  No psychiatric illness                                           --                     --                       --                                           23 (51.1%)             99 (92.5%)
                                                                                                                                                                                       
  *Medication* (N, % of group)[d](#tf0020){ref-type="table-fn"}                                                                                                                        
  No psychotropic medication                                       5 (10.4%)              6 (17.1%)                33 (100%)                                    45 (100%)              107 (100%)
  Amisulpiride                                                     5 (10.4%)              1 (2.9%)                 --                                           --                     --
  Aripiprazole                                                     4 (8.3%)               5 (14.3%)                --                                           --                     --
  Clozapine                                                        7 (14.6%)              --                       --                                           --                     --
  Flupentixol                                                      4 (8.3%)               --                       --                                           --                     --
  Olanzapine                                                       14 (29.2%)             10 (28.6%)               --                                           --                     --
  Quetiapine                                                       3 (6.3%)               1 (2.9%)                 --                                           --                     --
  Risperidone                                                      5 (10.4%)              11 (31.4%)               --                                           --                     --
  Other antipsychotic                                              9 (18.8%)              1 (2.9%)                 --                                           --                     --
  Lithium or Sodium Valproate                                      9 (18.8%)              6 (17.1%)                --                                           --                     --
  Antidepressant                                                   17 (35.4)              4 (11.4%)                                                                                    
  *Years in education* (M ± SD)[e](#tf0025){ref-type="table-fn"}   12.9 ± 2.2             14.4 ± 2.9               14.1 ± 3.1                                   12.5 ± 2.2             14.4 ± 2.6
                                                                                                                                                                                       
  *Ethnicity* (N, % of group)                                                                                                                                                          
  Caucasian                                                        44 (91.7%)             8 (17.4%)                20 (60.6%)                                   43 (95.6%)             76 (71.0%)
  African/Caribbean                                                2 (4.2%)               30 (65.2%)               8 (24.2%)                                    1 (2.2%)               25 (23.5%)
  Other/Mixed                                                      2 (4.2%)               8 (17.4%)                5 (15.2%)                                    1 (2.2%)               6 (5.6%)
                                                                                                                                                                                       
  *EEG lab* (N)                                                                                                                                                                        
  A (64 channels)                                                  --                     --                       33                                           --                     45
  B (40 channels)                                                  48                     46                       --                                           45                     62

ARMS = At risk mental state; MDD = Major Depressive Disorder; GAD = Generalised Anxiety Disorder;

2-tailed t-tests for age and chi square tests for gender, each group compared against the control group;

ARMS criteria: 67% attenuated psychotic symptoms, 10% brief limited intermittent psychotic symptoms (BLIPS), 10% BLIPS and attenuated symptoms, 3% genetic risk with a decline in function, 10% genetic risk with a decline in function and attenuated symptoms;

These individuals had a history of a non-psychotic illness in addition to an "at-risk mental state";

Data available for 76.1% of first episode group, percentage of 35 first episode patients with information available has been reported.

Data available for 78.9% of the total sample.

###### 

Average resting EEG amplitude across FZ, CZ and PZ (micro volts ± standard deviations) for all participant groups and frequency bands, uncorrected for covariates.

          Chronic patients   First episode patients   ARMS           Relatives      Controls
  ------- ------------------ ------------------------ -------------- -------------- --------------
  Delta   9.03 ± 2.63        8.08 ± 2.34              8.29 ± 2.05    7.17 ± 1.65    8.00 ± 1.94
  Theta   12.10 ± 5.28       9.57 ± 3.72              9.38 ± 3.29    8.49 ± 3.24    8.95 ± 2.81
  Alpha   8.57 ± 3.04        8.78 ± 4.44              8.60 ± 5.06    7.51 ± 3.84    8.95 ± 4.13
  Beta    11.73 ± 3.49       9.21 ± 3.30              10.23 ± 3.65   11.23 ± 5.46   10.56 ± 3.35

ARMS = At risk mental state

###### 

Summary of main significant findings, after correction for multiple testing (p = 0.05/4 = 0.0125).

  Delta frequency band           Theta frequency band           Alpha frequency band                 Beta frequency band
  ------------------------------ ------------------------------ ------------------------------------ ------------------------------------
  1.90--3.90 Hz                  4.39--7.32 Hz                  8.30--12.70 Hz                       13.20--21.00 Hz
                                                                                                     
  Chronic patients \> controls   Chronic patients \> controls   *No significant group differences*   *No significant group differences*
